Disease progression in amyotrophic lateral sclerosis: Identifying the cost-utility of riluzole by disease stage

European Journal of Health Economics

Volumn 3, Issue 3, 2002, Pages 156-165

  Tavakoli, Manouche ^a,b  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

ALS; Cost effectiveness; Cost utility; Markov models; Riluzole

Indexed keywords

RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; EXPERIENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR NEURON DISEASE; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

EID: 0036970163     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-002-0110-0     Document Type: Article

References (44)

1. Swash M, ed (2000) Clinical features and diagnosis of amyotrophic lateral sclerosis. London: Dunitz
2. Tavakoli M, Davies HTO, Malek M (1999) Modelling the long-term cost-effectiveness of riluzole for the treatment of amyotrophic lateral sclerosis. J Med Econ 2:1-14
3. Tavakoli M, Malek M (2001) The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. J Neurol Sci 191:95-102
4. Rivière M, Meininger V, Zeisser P, Munsat TL (1998) An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 55:526-528
5. Shaw PJ (1999) Motor neurone disease. BMJ 318 1118-1121
6. Norris F, Shepherd R, Denys E, et al (1993) Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 118:48-55
7. Bach JR (1993) Amyotrophic lateral sclerosis: communication status and survival with ventilatory support. Am J Phys Med Rehabil 72:343-349
8. Jablecki CK, Berry C, Leach J (1989) Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 12:833-841
9. Haverkamp LJ, Appel V, Appel SH (1995) Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118:707-719
10. Borasio GD, Voltz R (1997) Palliative care in amyotrophic lateral sclerosis. J Neurol 244 [Suppl 4]:S11-S17
11. de Belleroche J, Orrell RW, Virgo L (1996) Amyotrophic lateral sclerosis: recent advances in understanding disease mechanisms. J Neuropath Exp Neurol 55:747-757
12. Munsat TM, Riviere M, Swash M, Leclerc C (1998) Economic burden of amyotrophic lateral sclerosis in the United Kingdom. J Med Econ 1:235-245
13. Dubrovsky AL, Sica RE (1999) Current treatment pathways in ALS: a South American perspective. Neurology 53 [8 Suppl 5]:S11-S16
14. Rothstein JD (1995) Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 68:7-20
15. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330:585-591
16. Mizoule J, Meldrum B, Mazadier M, et al (1985) 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. I. Anticonvulsant properties. Neuropharmacology 24:767-773
17. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347:1425-1431
18. Stewart A, Sandercock J, Bryan S,et al (2001) The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review. Health Technol Assess 5 (2)
19. Sonnenberg FA, Beck RJ (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322-338
20. Drummond MF, O' Brien B, Stoddart GL, Torrance GW (2000) Methods for the economic evaluation of health care programmes. 2nd edn. Oxford: Oxford University Press
21. Torrance GW, Feeny D, Furlong W (2001) Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 21:329-334
22. Torrance GW (1987) Utility approach to measuring health-related quality of life. J Chronic Dis 40:593-603
23. Torrance GW, Boyle MH, Horwood SP (1982) Application of multi-attribute utility theory to measure social preferences for health states. Oper Res 310:1043-1069
24. Green C, Brazier J, Deverill M (2000) Valuing health-related quality of life: a review of health state valuation techniques. Pharmacoeconomics 17:151-165
25. Kiebert GM, Green C, Murphy C, et al (2001) Patients' health related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci 191:87-93
26. Torrance GW (1986) Measurement of health state utilities for economic appraisal: a review. J Health Econ 5:1-30
27. Robinson A, Loomes G, Jones-Lee M (2001) Visual analog scales, standard gambles, and relative risk aversion. Med Decis Making 21:17-27
28. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q (1996) Multiattribute utility function for a comprehensive health status classification system. Health utilities index mark 2. Med Care 34:702-722
29. Feeny DH, Torrance GW (1989) Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples. Med Care 27:S190-S204
30. Goodin RE (1982) Discounting discounting. J Public Policy 2:53-72
31. Parsonage M, Neuburger H (1992) Discounting and health benefits. Health Econ 1:71-79
32. Brouwer W, van Hout B, Rutten F (2000) A fair approach to discounting future effects: taking a societal perspective. J Health Serv Res Policy 5:114-118
33. Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13:397-409
34. MIMS (2000) MIMS. London: Haymarket Medical.
35. Barisano A, Kramer JS (1998) Treatment of patients with ALS: implications for the managed care pharmacist. J Manage Care Pharm 4:599-604
36. Corr B, Frost E, Traynor BJ, Hardiman O (1998) Service provision for patients with ALS/MND: a cost-effective multidisciplinary approach. J Neurol Sci 160 [Suppl 1]:S141-S145
37. Klein LM, Forshew DA (1996) The economic impact of ALS. Neurology 47 [4 Suppl 2]:S126-S129
38. Mitchell JD, Davies RB, al Hamad A, Gatrell AC, Batterby G (1995) MND risk factors: an epidemiological study in the north west of England. J Neurol Sci 129 [Suppl]:61-64
39. James CM, Harper PS, Wiles CM (1994) Motor neurone disease-a study of prevalence and disability. Q J Med 87:693-699
40. Mitchell JD, Gibson HN, Gatrell A (1990) Amyotrophic lateral sclerosis in Lancashire and South Cumbria, England, 1976-1986. A geographical study. Arch Neurol 47:875-880
41. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O (1999) Incidence and prevalence of ALS in Ireland 1995-1997: a populationbased study. Neurology 52:504-509
42. Messori A, Trippoli S, Becagli P, Zaccara G (1999) Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Pharmacoeconomics 16:153-163
43. Ginsberg GM, Lev B (1997) Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis. Pharmacoeconomics 12:578-584
44. Office for National Statistics (1999) The blue book: United Kingdom National Accounts. London: The Stationary Office